Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies Research Letter

   

Authors:	Stuver, R.; Shah, G. L.; Korde, N. S.; Roeker, L. E.; Mato, A. R.; Batlevi, C. L.; Chung, D. J.; Doddi, S.; Falchi, L.; Gyurkocza, B.; Hamilton, A.; Lin, Y. H.; Jakubowski, A. A.; Joffe, E.; Landau, H. L.; Lin, R. J.; Mailankody, S.; Palomba, M. L.; Park, J. H.; Perales, M. A.; Ponce, D. M.; Ramanathan, L. V.; Salles, G. A.; Scordo, M.; Seo, S. K.; Shah, U. A.; Stein, E. M.; Straus, D.; Usmani, S. Z.; Young, J. W.; Zelenetz, A. D.; Noy, A.; Vardhana, S. A.
Title:	Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
Keywords:	adult; major clinical study; drug activity; drug efficacy; nonhuman; follow up; letter; wild type; monoclonal antibody; antibodies, monoclonal; hematologic malignancy; nonhodgkin lymphoma; hematologic neoplasms; drug combination; single drug dose; drug combinations; observational study; immunoglobulin g antibody; receptor binding; hematologic disease; antibody titer; randomized controlled trial (topic); virus mutation; neutralizing antibody; antibodies, neutralizing; virus neutralization; severe acute respiratory syndrome; pre-exposure prophylaxis; humans; human; virus spike protein; chimeric antigen receptor t-cell immunotherapy; severe acute respiratory syndrome coronavirus 2; coronavirus disease 2019; covid-19; sars-cov-2; cilgavimab plus tixagevimab; sotrovimab; cilgavimab; cilgavimab and tixagevimab drug combination; tixagevimab; patient history of stem cell transplantation; sars-cov-2 omicron; surrogate virus neutralization test
Journal Title:	Cancer Cell
Volume:	40
Issue:	6
ISSN:	1535-6108
Publisher:	Cell Press
Date Published:	2022-06-13
Start Page:	590
End Page:	591
Language:	English
DOI:	10.1016/j.ccell.2022.05.007
PUBMED:	35598602
PROVIDER:	scopus
PMCID:	PMC9108069
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85132188475&doi=10.1016%2fj.ccell.2022.05.007&partnerID=40&md5=39a138cbc56b914e0cc221f697605d3f
Notes:	The PDF includes a typo in Heather Landau's name; The author's middle initial is formatted as: Heather L. Landau, the correct middle initial is: Heather J. Landau -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/196170